Table 4.
Joint analysis of GATA3 single nucleotide polymorphisms and breast cancer outcomes in the S8897 trial and Pathways Study
| Genotype | # events/patients | Adjusted HR (95% CI) | Adjusted P |
|---|---|---|---|
| A. Overall survival | |||
| rs3802604 | |||
| AA | 34/261 | 1.00 | |
| GA | 44/368 | 0.98 (0.62-1.53) | 0.92 |
| GG | 23/122 | 1.59 (0.94-2.71) | 0.09 |
| Per risk allele | 1.23 (0.93-1.63) | 0.15 | |
| rs568727 | |||
| CC | 39/290 | 1.00 | |
| AC | 37/364 | 0.71 (0.45-1.11) | 0.13 |
| AA | 25/96 | 1.86 (1.11-3.12) | 0.02 |
| Per risk allele | 1.26 (0.94-1.68) | 0.13 | |
| B. Disease-free survival | |||
| rs3802604 | |||
| AA | 52/261 | 1.00 | |
| GA | 71/368 | 0.96 (0.67-1.38) | 0.84 |
| GG | 33/122 | 1.49 (0.96-2.30) | 0.08 |
| Per risk allele | 1.18 (0.94-1.49) | 0.15 | |
| rs568727 | |||
| CC | 57/290 | 1.00 | |
| AC | 66/364 | 0.85 (0.59-1.21) | 0.37 |
| AA | 33/96 | 1.80 (1.16-2.79) | 0.009 |
| Per risk allele | 1.25 (0.98-1.59) | 0.07 | |
Footnote: Hazard ratios (HRs), 95% confidence intervals (CIs) and p-values were derived from Cox hazard regression models with adjustment for study, age at enrollment, race and ethnicity, and treatment arms. Estimates of per risk allele were derived from an additive genetic model by treating genotypes as 0, 1 and 2 according to the copy number of risk allele.